Tracer library / [177Lu]Lu-PSMA-ALB-56
[177Lu]Lu-PSMA-ALB-56
Also written as [Lu-177]Lu-PSMA-ALB-56
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 3
What it is
- Compound class
- PSMA-targeted albumin-binding radioligand (small-molecule PSMA inhibitor with albumin-binding entity)
- Target / mechanism
- PSMA (prostate-specific membrane antigen) radioligand with albumin-binding properties to increase tumor uptake PMID 32949253
- Clinical application
- Radionuclide therapy for metastatic castration-resistant prostate cancer (mCRPC) PMID 32949253
- Theranostic pair
- —
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| GAIA Elysia-Raytest | vendor cassette | none | — | <70% | PSMA-ALB-56 MedChemExpress | 41096906 2025 Int J Mol Sci The automated radiosynthesis of [177Lu]Lu-PSMA-ALB-56 was developed and performed on a GAIA® synthesis module |
| GAIA Elysia-Raytest | vendor cassette | SPE | 86.52 ± 0.48% | 98.92 ± 0.12% | PSMA-ALB-56 MedChemExpress | 41096906 2025 Int J Mol Sci The automated radiosynthesis of [177Lu]Lu-PSMA-ALB-56 was developed and performed on a GAIA® synthesis module - this process also provided very good RCYs (mean value adjusted by RCP determined by HPLC: 86.52 ± 0.48%) |
| Manual synthesis | — | none | — | ≥ 98% | PSMA-ALB-56 | 35635566 2022 Eur J Nucl Med Mol Imaging The radiolabeling of the PSMA ligands with lutetium-177 (no-carrier-added; in 0.04 M HCl; ITM Medical Isotopes GmbH, Germany) was performed under standard labeling conditions at pH 4.5 as previously reported |
Precursor
- Common precursor
- —
- Suppliers seen in the literature
- —
- Cited suppliers in indexed syntheses
- MedChemExpress
- Typical final purification
- —
Need this precursor?We can point you to suppliers for [177Lu]Lu-PSMA-ALB-56, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 4 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 35635566: 'PSMA-ALB-56 modified with a 4-(p-tolyl)butanoate entity (blue) as an albumin binding entity conjugated via lysine residue'.